Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Simple item page
dc.contributor.authorI-SPY 1 TRIAL Investigators
dc.contributor.otherUniversity of California San Francisco
dc.contributor.otherUTMD Anderson Cancer Center
dc.contributor.otherUniversity of North Carolina
dc.contributor.otherUniversity of North Carolina Chapel Hill
dc.contributor.otherUniversity of Pennsylvania
dc.contributor.otherOregon Health & Science University
dc.contributor.otherUnited States Department of Energy (DOE)
dc.contributor.otherLawrence Berkeley National Laboratory
dc.contributor.otherUniversity of California Berkeley
dc.contributor.otherBoston University
dc.contributor.otherMemorial Sloan Kettering Cancer Center
dc.contributor.otherUniversity of Alabama Tuscaloosa
dc.contributor.otherYeshiva University
dc.contributor.otherUniversity of Southern California
dc.contributor.otherUniversity of Washington
dc.contributor.otherGeorgetown University
dc.contributor.otherUniversity of Chicago
dc.contributor.otherYale University
dc.contributor.otherNew York University
dc.date.accessioned2023-09-28T19:05:31Z
dc.date.available2023-09-28T19:05:31Z
dc.date.issued2012
dc.description.abstractNeoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with a parts per thousand yen3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.en_US
dc.format.mediumelectronic
dc.format.mimetypeapplication/pdf
dc.identifier.citationEsserman, L. J., Berry, D. A., Cheang, M. C. U., Yau, C., Perou, C. M., Carey, L., DeMichele, A., Gray, J. W., Conway-Dorsey, K., Lenburg, M. E., Buxton, M. B., Davis, S. E., van’t Veer, L. J., Hudis, C., Chin, K., Wolf, D., Krontiras, H., Montgomery, L., … Hylton, N. (2011). Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). In Breast Cancer Research and Treatment (Vol. 132, Issue 3, pp. 1049–1062). Springer Science and Business Media LLC. https://doi.org/10.1007/s10549-011-1895-2
dc.identifier.doi10.1007/s10549-011-1895-2
dc.identifier.orcidhttps://orcid.org/0000-0002-5760-4708
dc.identifier.orcidhttps://orcid.org/0000-0001-9827-2247
dc.identifier.orcidhttps://orcid.org/0000-0001-7144-8791
dc.identifier.orcidhttps://orcid.org/0000-0001-5718-2501
dc.identifier.urihttps://ir.ua.edu/handle/123456789/10840
dc.languageEnglish
dc.language.isoen_US
dc.publisherSpringer
dc.rights.licenseAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectBreast cancer
dc.subjectNeoadjuvant chemotherapy
dc.subjectMolecular biomarkers
dc.subjectPathologic complete response
dc.subjectGENE-EXPRESSION SIGNATURE
dc.subjectSURGICAL ADJUVANT BREAST
dc.subjectPRIMARY TUMOR
dc.subjectWOMEN
dc.subjectMACROPHAGES
dc.subjectPREDICTOR
dc.subjectPATTERNS
dc.subjectSUBTYPES
dc.subjectOncology
dc.titleChemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)en_US
dc.typeArticle
dc.typetext
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1007s10549-011-1895-2.pdf
Size:
912.6 KB
Format:
Adobe Portable Document Format
Download
Collections
Research and Publications - Department of Health Science